Revolving Door Policy
Government corruption, kickbacks, lobbyists, unethical policies in government. Legislation without regulation. The revolving door of deceitful individuals from unscrupulous corporations to government entities has created a cesspool of hazardous regulations, and unethical profits.
What is the Revolving Door?
In politics, the "revolving door" is a movement of personnel between roles as legislators and regulators in the industries affected by the legislation and regulation.
In some cases, the roles are performed in sequence but in certain circumstances may be performed at the same time. Political analysts claim that an unhealthy relationship can develop between the private sector and government, based on the granting of reciprocated privileges to the detriment of the nation and can lead to regulatory capture.
Governments hire industry professionals for their private sector experience, their influence within corporations that the government is attempting to regulate or do business with, and in order to gain political support (donations and endorsements) from private firms.
Government Hires Industry Professionals
Industry, in turn, hires people out of government positions to gain personal access to government officials, seek favorable legislation/regulation and government contracts in exchange for high-paying employment offers, and get inside information on what is going on in government.
The lobbying industry is especially affected by the revolving door concept, as the main asset for a lobbyist is contacts with and influence on government officials. This industrial climate is attractive for ex-government officials. It can also mean substantial monetary rewards for the lobbying firms and government projects and contracts in the hundreds of millions for those they represent. -Wikipedia
This is a list of men and women whom we have
put our trust in for our safety.
Now Vice President for Food & Agriculture of the Biotechnology Industry Organization (BIO). Largest trade organization to serve and represent the biotechnology industry in the United States and around the world.
Newsletter Sign Up!
Eden's Product Picks
Former administrator of the Animal and Plant Health Inspection Service (APHIS) of the United States Department of Agriculture, former chair and vice-chair of the United States Department of Agriculture Biotechnology Council, former member of the U.S. Food and Drug Administration (FDA) food advisory committee.
Still later Deputy Commissioner for Policy at the United States Food and Drug Administration. And later with the law firm of King & Spaulding, now head of the Washington, D.C. office of Monsanto Corporation.
Former microbial biotechnology researcher at Monsanto Corporation in St. Louis, Missouri, now with the United States Environmental Protection Agency Environmental Effects Laboratory, Western Ecology Division.
Former Secretary of the U.S. Department of Agriculture, former U.S. Trade Representative (who led the U.S. team in negotiating the U.S. Canada Free Trade Agreement and helped launch the Uruguay Round of the GATT negotiations), now a member of the board of directors of Mycogen Corporation, whose majority owner is Dow Agro Sciences, a wholly owned subsidiary of the Dow Chemical Company.
(An FDA ‘primary reviewer for all rbST and other dairy drug production applications”) were the subjects of a U.S. General Accounting Office (GAO) investigation in 1994 for their role in the U.S. Food and Drug Administration’s approval of Posilac, Monsanto Corporation’s formulation of recombinant bovine growth hormone (rbST or rBGH). The GAO Office found “no conflicting financial interests with respect to the drug’s approval” and only “one minor deviation from now superseded FDA regulation”. (Quotations are from the 1994 GAO report).
Exert from the Supreme Court case, No. 06-1249
Wyeth a pharmaceutical company, Petitioner.
Diana Levine, Respondent.
As Senator Charles Grassley stated on September 20, 2006
“The FDA has lost its way and ‘sold out’ to the industries it is charged to regulate.”
Indeed, conflicts of interest by the Advisory Committee members appointed by the FDA to investigate and approve medications for distribution, have become endemic. Advisory Committee members frequently receive funds from the pharmaceutical companies which manufacture the drugs upon which the committee makes determinations of safety and efficacy. The FDA is well aware of the conflicts of interest of its appointees and routinely waives the conflicts as a matter of standard practice. As a result, excessively dangerous drugs are frequently approved by the agency for general consumption and sale.
In reality, the FDA has become subverted by the industries it regulates. It is overtly attacked by whistleblowers, Congress and watchdog groups for incompetence and dishonesty. The FDA has failed to perform its duty of preventing the distribution of dangerous drugs or of adequately warning the public of the dangers of drugs once they are known. In the past several years, the Commissioner and executives of the FDA have been called on the carpet before angry Congressional committees to explain why they ordered FDA scientists not to reveal the dangers of some medications and why the FDA permits persons with blatant conflicts of interest to hold positions of great responsibility over the approval of drugs. Because the FDA has been unable to maintain its own internal ethical standards, it has been the subject of recent legislative attempts to restore order within its ranks.
You Might Also Like
As an affiliate of Amazon, we endeavor to offer the best quality and lowest prices as always through Amazon.com.
Your purchase helps partner with us in supporting this website and the valuable work we do for you.
We thank you and wish you good health, wellness and Love.
Disclaimer: Eden’s Corner does not endorse some products you may find (below) on Amazon. Amazon does their best to offer you products that honor our philosophy.